4.37
1.35%
-0.06
Handel nachbörslich:
4.37
Schlusskurs vom Vortag:
$4.43
Offen:
$4.44
24-Stunden-Volumen:
26,869
Relative Volume:
0.56
Marktkapitalisierung:
$186.81M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-17.97M
KGV:
-7.0484
EPS:
-0.62
Netto-Cashflow:
$-17.74M
1W Leistung:
+1.16%
1M Leistung:
+0.23%
6M Leistung:
+45.67%
1J Leistung:
+72.05%
Diamedica Therapeutics Inc Stock (DMAC) Company Profile
Firmenname
Diamedica Therapeutics Inc
Sektor
Branche
Telefon
(763) 496-5454
Adresse
301 CARLSON PARKWAY, MINNEAPOLIS, MN
Diamedica Therapeutics Inc Stock (DMAC) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2021-04-09 | Eingeleitet | Oppenheimer | Outperform |
2021-02-17 | Eingeleitet | ROTH Capital | Buy |
2020-10-30 | Eingeleitet | Guggenheim | Buy |
2020-07-08 | Eingeleitet | Maxim Group | Buy |
2019-04-30 | Eingeleitet | Dougherty & Company | Buy |
2019-03-05 | Eingeleitet | Lake Street | Buy |
Alle ansehen
Diamedica Therapeutics Inc Aktie (DMAC) Neueste Nachrichten
Blue Trust Inc. Makes New Investment in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) - Defense World
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Sees Large Growth in Short Interest - MarketBeat
Best Momentum Stocks to Buy for October 14th - Yahoo Canada Finance
Head to Head Contrast: DiaMedica Therapeutics (NASDAQ:DMAC) versus Provectus Biopharmaceuticals (OTCMKTS:PVCT) - Defense World
DiaMedica shares maintain Buy rating from H.C. Wainwright - Investing.com
DiaMedica shares maintain Buy rating from H.C. Wainwright By Investing.com - Investing.com South Africa
DiaMedica gets SAHPRA approval for Phase II preeclampsia treatment trial - Yahoo Finance
DiaMedica advances preeclampsia treatment with trial approval By Investing.com - Investing.com South Africa
DiaMedica advances preeclampsia treatment with trial approval - Investing.com India
DiaMedica Therapeutics Announces Regulatory Approval to Begin Phase 2 Trial of DM199 in the Treatment of Preeclampsia - Business Wire
Research Analysts Offer Predictions for DiaMedica Therapeutics Inc.'s Q3 2024 Earnings (NASDAQ:DMAC) - MarketBeat
H.C. Wainwright initiates DiaMedica shares with Buy rating on stroke treatment By Investing.com - Investing.com South Africa
H.C. Wainwright initiates DiaMedica shares with Buy rating on stroke treatment - Investing.com India
DiaMedica Therapeutics (NASDAQ:DMAC) Coverage Initiated by Analysts at HC Wainwright - MarketBeat
DiaMedica: Readying For REDUX Readout - RTTNews
Magnolia Capital Advisors LLC Buys New Stake in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) - Defense World
Point72 DIFC Ltd Acquires Shares of 2,848 Mettler-Toledo International Inc. (NYSE:MTD) - Defense World
Commonwealth Equity Services LLC Invests $303,000 in Diebold Nixdorf, Incorporated (NYSE:DBD) - Defense World
US FDA Closes Out Problem Applications One Federal Register Notice At A Time - Pink Sheet
Ameritas Investment Partners Inc. Has $1.82 Million Stake in Dolby Laboratories, Inc. (NYSE:DLB) - Defense World
Domino’s Pizza, Inc. (NYSE:DPZ) Position Lowered by Epoch Investment Partners Inc. - Defense World
Victory Capital Management Inc. Sells 10,924 Shares of Dolby Laboratories, Inc. (NYSE:DLB) - Defense World
Dolby Laboratories, Inc. (NYSE:DLB) Shares Sold by Federated Hermes Inc. - Defense World
Deftones’ Album Rises To A New Peak–Nearly 20 Years After Its Release - Forbes
Deutsche Telekom downgraded to Neutral from Outperform at Oddo BHF - TipRanks
Insiders See US$9.05m Investment In DiaMedica Therapeutics Jump Last Week - Simply Wall St
DiaMedica Therapeutics (NASDAQ:DMAC) Shares Up 2.7% - Defense World
DiaMedica Therapeutics (NASDAQ:DMAC) Trading Up 2.7% - MarketBeat
DMAC stock touches 52-week high at $4.11 amid bullish trend - Investing.com
DiaMedica Therapeutics Upcoming Conference Participation - Business Wire
Is Atossa Genetics (ATOS) Outperforming Other Medical Stocks This Year? - Yahoo Finance
DMAC stock touches 52-week high at $3.85 amid robust gains - Investing.com
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Shares Purchased by Vanguard Group Inc. - Defense World
Vanguard Group Inc. Acquires 211,351 Shares of DiaMedica Therapeutics Inc. (NASDAQ:DMAC) - MarketBeat
Oppenheimer Reiterates “Outperform” Rating for DiaMedica Therapeutics (NASDAQ:DMAC) - Defense World
DiaMedica Therapeutics' (DMAC) Outperform Rating Reaffirmed at Oppenheimer - MarketBeat
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Short Interest Update - MarketBeat
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Short Interest Down 17.0% in July - Defense World
Earnings call: DiaMedica Therapeutics highlights solid progress in Q2 - Investing.com
Earnings call: DiaMedica Therapeutics highlights solid progress in Q2 By Investing.com - Investing.com Canada
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q2 2024 Earnings Call Transcript - Insider Monkey
DiaMedica Therapeutics Inc. (DMAC) Q2 2024 Earnings Call Transcript - Seeking Alpha
DiaMedica Therapeutics (NASDAQ:DMAC) Releases Earnings Results - MarketBeat
DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2024 Financial Results - Business Wire
DiaMedica Therapeutics (DMAC) to Release Earnings on Wednesday - Defense World
DiaMedica Therapeutics (DMAC) Scheduled to Post Earnings on Wednesday - MarketBeat
Are Medical Stocks Lagging DiaMedica Therapeutics (DMAC) This Year? - Yahoo Finance
DiaMedica Therapeutics to Provide a Business Update and Report Second Quarter 2024 Financial Results August 8, 2024 - Business Wire
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Short Interest Up 10.8% in July - MarketBeat
Short Interest in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Grows By 10.8% - Defense World
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Short Interest Up 22.1% in June - MarketBeat
Finanzdaten der Diamedica Therapeutics Inc-Aktie (DMAC)
Umsatz
Nettogewinn
Free Cashflow
ENV
Diamedica Therapeutics Inc-Aktie (DMAC) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
STAHLBERG JAN | 10% Owner |
Jun 28 '24 |
Buy |
2.50 |
1,200,000 |
3,000,000 |
5,221,608 |
Wambeke David J. | Chief Business Officer |
Nov 16 '23 |
Buy |
2.46 |
20,000 |
49,200 |
527,114 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):